Jonathan R. Whitfield and Laura Soucek
Mar 26, 2025, 00:28
MYC in cancer: from undruggable target to clinical trials
Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a paper Jonathan R. Whitfield and Laura Soucek authored on X:
“MYC in cancer: from undruggable to clinical trials.
Despite its key role in tumor growth, no MYC inhibitor is yet approved. This review explores emerging strategies and promising candidates in trials.”
MYC in cancer: from undruggable target to clinical trials
Authors: Jonathan R. Whitfield and Laura Soucek
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 31, 2025, 15:57
Mar 31, 2025, 15:22
Mar 31, 2025, 14:52
Mar 31, 2025, 14:52
Mar 31, 2025, 14:46
Mar 31, 2025, 14:02